These results support our hypothesis that Lenvatinib exerts anticancer effects partially by inhibiting MEK/ERK signaling pathway via targeting receptor tyrosine kinases, while AKT signaling activation attenuates HCC cells' sensitivity to Lenvatinib. This evidence concerns the gene MAP2K7 and hepatocellular carcinoma.